Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
Cash from Operating Activities
Ondine Biomedical Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Cash from Operating Activities
-CA$13.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Cash from Operating Activities
-$5.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
38%
|
CAGR 10-Years
3%
|
|
|
Profound Medical Corp
TSX:PRN
|
Cash from Operating Activities
-$23.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Opsens Inc
TSX:OPS
|
Cash from Operating Activities
-CA$14.5m
|
CAGR 3-Years
-144%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
-46%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Cash from Operating Activities
-CA$3.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
1%
|
|
|
MedMira Inc
XTSX:MIR
|
Cash from Operating Activities
-CA$3.3m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
3%
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Cash from Operating Activities?
Cash from Operating Activities
-13.7m
CAD
Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Cash from Operating Activities amounts to -13.7m CAD.
What is Ondine Biomedical Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
16%
Over the last year, the Cash from Operating Activities growth was 16%.
You don't have any saved screeners yet